CAPITOL COUNSEL LLC for BIOGEN, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare beneficiary access to treatments for Alzheimers disease, including Medicare Part B access issues, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. No: 117-169), including Subtitle B - Prescription Drug Pricing Reform, Part 1 - Lowering Prices through Drug Price Negotiations; and Sections 11402 and 11403 regarding Medicare Part B payment policies for certain biologicals; and provisions regarding application of Maximum Fair Prices and Conforming Amendments [Section 11001, re: Providing for Lower Prices; Subsection (b)] to modify Medicare Part B reimbursement for selected drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY CARROLL | — |
| AARON COHEN | — |
| SHANNON FINLEY | — |
| DENISE HENRY MORRISEY | — |
| ANN JABLON | — |
| JONATHAN KOTT | — |
Health Issues HCR
Patient access to treatments for Alzheimers disease, and 340B Drug Pricing Program related issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY CARROLL | — |
| AARON COHEN | — |
| SHANNON FINLEY | — |
| DENISE HENRY MORRISEY | — |
| ANN JABLON | — |
| JONATHAN KOTT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.